Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition

Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition

Abstract A subset of lung adenocarcinomas is driven by the EML4‐ALK translocation. Even though ALK inhibitors in the clinic lead to excellent initial responses, acquired resistance to these inhibitors due to on‐target mutations or parallel pathway alterations is a major clinical challenge. Exploring...

Full description

Bibliographic Details
Main Authors: Athanasios R Paliouras, Marta Buzzetti, Lei Shi, Ian J Donaldson, Peter Magee, Sudhakar Sahoo, Hui‐Sun Leong, Matteo Fassan, Matthew Carter, Gianpiero Di Leva, Matthew G Krebs, Fiona Blackhall, Christine M Lovly, Michela Garofalo
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:EMBO Molecular Medicine
Subjects:
ALK/EML4 translocation
ALKi
CDKi
drug resistance
NSCLC
Online Access:https://doi.org/10.15252/emmm.201911099

Internet

https://doi.org/10.15252/emmm.201911099

Similar Items